239O RECORD-4: Multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Asian versus non-Asian population subanalysis

Renal Cell ◽

Asian Population ◽

Second Line ◽

Phase 2 ◽

Phase 2 Trial ◽

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

BMC Cancer ◽

10.1186/s12885-018-4091-5 ◽

2018 ◽

Vol 18 (1) ◽

Author(s):

Lin Yang ◽

Anna Alyasova ◽

Dingwei Ye ◽

Antonia Ridolfi ◽

Luca Dezzani ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Asian Population ◽

Second Line ◽

Phase 2 ◽

Phase 2 Trial ◽

2634 RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Asian versus non-Asian population subanalysis

European Journal of Cancer ◽

10.1016/s0959-8049(16)31451-4 ◽

2015 ◽

Vol 51 ◽

pp. S524

Author(s):

L. Yang ◽

A. Alyasova ◽

D. Ye ◽

A. Karpenko ◽

H. Li ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Asian Population ◽

Second Line ◽

Phase 2 ◽

Phase 2 Trial ◽

2620 RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Pooled anti-VEGF cohort subanalysis

European Journal of Cancer ◽

10.1016/s0959-8049(16)31438-1 ◽

2015 ◽

Vol 51 ◽

pp. S518-S519

Author(s):

B. Alekseev ◽

L. Yang ◽

A. Alyasova ◽

D. Ye ◽

A. Karpenko ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Second Line ◽

Phase 2 ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Anti Vegf

Camrelizumab plus famitinib in patients with advanced or metastatic renal cell carcinoma: data from an open-label, multicenter phase 2 basket study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-1698 ◽

2021 ◽

pp. clincanres.1698.2021

Author(s):

Yuan-Yuan Qu ◽

Hai-Liang Zhang ◽

Hongqian Guo ◽

Hong Luo ◽

Qing Zou ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Open Label ◽

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503.

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2016.12.023 ◽

2017 ◽

Vol 35 (3) ◽

pp. 117-118 ◽

Cited By ~ 2

Author(s):

Raman Jay ◽

RR McKay ◽

L Werner ◽

MB Atkins ◽

EM Van Allen ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Poor Risk ◽

Phase 2 Trial

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30196-6 ◽

2016 ◽

Vol 17 (9) ◽

pp. 1317-1324 ◽

Cited By ~ 93

Author(s):

Brian I Rini ◽

Tanya B Dorff ◽

Paul Elson ◽

Cristina Suarez Rodriguez ◽

Dale Shepard ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Active Surveillance ◽

Renal Cell ◽

Phase 2 ◽

Phase 2 Trial ◽

Prospective Phase

4510 POSTER A phase 2 trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71141-2 ◽

2007 ◽

Vol 5 (4) ◽

pp. 301 ◽

Cited By ~ 1

Author(s):

T.E. Hutson ◽

D.J. George ◽

M.D. Michaelson ◽

J.E. Rosenberg ◽

R.M. Bukowski ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 2 ◽

Circulating Biomarkers ◽

Phase 2 Trial

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70464-9 ◽

2013 ◽

Vol 14 (12) ◽

pp. 1233-1242 ◽

Cited By ~ 157

Author(s):

Brian I Rini ◽

Bohuslav Melichar ◽

Takeshi Ueda ◽

Viktor Grünwald ◽

Mayer N Fishman ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Dose Titration ◽

Phase 2 ◽

First Line ◽

Double Blind ◽

Phase 2 Trial

SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.4500 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4500-4500 ◽

Cited By ~ 23

Author(s):

R. J. Motzer ◽

B. I. Rini ◽

M. D. Michaelson ◽

B. G. Redman ◽

G. R. Hudes ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Antitumor Activity ◽

Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitor ◽

Second Line ◽

Phase 2 ◽

Second Line Therapy ◽

Phase 2 Trial ◽

Line Therapy

SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.4500 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4500-4500 ◽

Cited By ~ 5

Author(s):

R. J. Motzer ◽

B. I. Rini ◽

M. D. Michaelson ◽

B. G. Redman ◽

G. R. Hudes ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Antitumor Activity ◽

Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitor ◽

Second Line ◽

Phase 2 ◽

Second Line Therapy ◽

Phase 2 Trial ◽

Line Therapy